Akari Therapeutics Faces Nasdaq Compliance Challenge Amid Volatile Trading

The biotechnology firm Akari Therapeutics finds itself navigating a critical period as it confronts the dual challenge of potential stock exchange delisting and unpredictable market performance. With a key regulatory deadline approaching, investors are watching closely to see if the company can orchestrate a recovery.

Akari Therapeutics has been formally notified by Nasdaq regulators that it has fallen out of compliance with listing requirements. The issue stems from the company’s share price remaining below the mandatory $1.00 threshold for 30 consecutive trading sessions.

Management now faces a 180-day window to regain compliance, with a deadline of May 25, 2026. To satisfy exchange rules, the stock must close at or above $1.00 per share for Read more...